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The non-involved, healthy-looking skin of psoriatic pa-
tients displays inherent characteristics that make it pro-
ne to develop typical psoriatic symptoms. Our primary 
aim was to identify genes and proteins that are diffe-
rentially regulated in the non-involved psoriatic and the 
normal epidermis, and to discover regulatory networks 
responsible for these differences. A cDNA microarray ex-
periment was performed to compare the gene expression 
profiles of 4 healthy and 4 psoriatic non-involved epider-
mis samples in response to T-cell lymphokine induction 
in organotypic cultures. We identified 61 annotated genes 
and another 11 expressed transcripts that were differen-
tially regulated in the psoriatic tissues. Bioinformatics 
analysis suggested that the regulation of cell morpholo-
gy, development and cell death is abnormal, and that the 
metabolism of small molecules and lipids is differentially 
regulated in psoriatic epidermis. Our results indicate 
that one of the early steps of psoriasis pathogenesis may 
be the abnormal regulation of IL-23A and IL-1B genes in 
psoriatic keratinocytes. Key words: non-involved psoriatic 
epidermis; T-cell lymphokines; gene expression analysis; 
regulatory networks; IL-23A.
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Psoriasis is a hyperproliferative, inflammatory skin 
disease that affects ~2–3% of the Caucasian popula-
tion (OMIM 177900). It is a complex disease in which 
multiple genetic factors, together with not well-defined 
environmental factors, lead to the appearance of the di-
sease phenotype: sharply demarcated, red, scaly lesions 
of varying extent. A number of genes and biological pro-
cesses are involved in the development of the symptoms, 
and the disease is genetically heterogeneous (1). 
The trigger of keratinocyte hyperproliferation in the 
initiation of the psoriatic lesion is thought to be the 
activation of the cellular immune system, with T cells, 
dendritic cells and various immune-related cytokines 
and chemokines implicated in the pathogenesis (2). 
Keratinocytes in the otherwise healthy-looking, non-
involved skin areas of psoriatic patients already display 
an inherent sensitivity to proliferative signals, and this 
plays a crucial role in the development of psoriatic 
lesions (3, 4).
Large-scale gene expression profiling methods (dif-
ferential display and microarray) have recently become 
very popular, and have been used to identify transcripts 
with altered gene expressions in psoriasis (5–7). These 
experiments have identified many genes and cellular 
processes playing important roles in the disease. 
Besides the already known, marked differences in 
the global gene expression profiles of psoriatic and 
normal keratinocytes, the non-involved skin of psoria-
tic patients also differs considerably from the normal, 
healthy skin at the transcriptional level. This is clearly 
indicated by the above-mentioned functional differences 
in proliferative response of healthy and of psoriatic non-
involved keratinocytes. Such differentially expressed 
transcripts and novel psoriasis susceptibility factors 
have been successfully identified (3, 5, 8).
In order to broaden our investigations of the differen-
tial responses of normal and of psoriatic non-involved 
skin samples, we have now performed a microarray 
analysis to compare gene expression changes in epider-
mis samples treated in organotypic skin cultures with a 
mixture of interferon (IFN)-γ, granulocyte-macrophage 
colony stimulating factor (GM-CSF) and interleukin 
(IL)-3, a special combination that has been shown to 
mimic the effect of psoriatic T-cell lymphokines (3). 
Besides the identification of already known and novel 
susceptibility genes, our analysis of the possible con-
nections between them led to the identification of cel-
lular processes that can be inherently disregulated in the 
healthy-looking skin of patients in response to various 
external signals. Our results suggest the fine tuning of 
cell death regulation and the metabolism of lipids as 
the primary processes that are disregulated in the non-
involved epidermis of psoriatic patients in response to 
external signals, and which may therefore play a key 
role in the early events of the disease mechanism. 
One of the most interesting genes exhibiting altered 
gene expression changes in the psoriatic non-lesional 
epidermis following T-cell lymphokine treatment was 
IL-23A. A growing volume of evidence suggests that 
abnormal regulation of the IL-23 cytokine may be cru-
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cial for the initiation of various organ-specific chronic 
inflammatory diseases, such as psoriasis and inflam-
matory bowel disease (IBD) (9, 10). 
METHODS
Patients and samples
Shave biopsy samples were taken from the non-involved buttock 
area of 4 young male psoriasis patients and 4 age and gender-
matched healthy controls. Tissue samples were obtained with 
the subjects’ informed consent and the approval of the Ethics 
Committee of the University of Szeged. The study was perfor-
med in accordance with the Declaration of Helsinki guidelines 
and its later revision.
Organotypic skin cultures
All shave biopsies were cut into two pieces, and organotypic 
skin cultures were established from each piece (7). Briefly, 
skin specimens were placed on cellulose acetate/cellulose 
nitrate filters with 2.2-μm porosity (Millipore) and transferred 
to a stainless steel grid platform in a 6-well plate. Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 12 mM 
glutamine, 100 units/ml penicillin and 100 μg/ml streptomycin 
(all from Life Technologies, Carlsbad, CA) was used as a culture 
medium. In case of each donor one of the resulting organotypic 
cultures were left untreated and only incubated for 72h, while 
the other half was treated with 1 ng/ml IFNγ, 1 ng/ml gM-CsF 
and 0.3 ng/ml IL-3. Tissue samples were maintained at the air/
liquid interface under standard culturing conditions (at 37°C in a 
5% CO2 atmosphere) for 72 h (3, 7). The tissue specimens were 
then incubated in Dispase solution (grade II, Roche Applied 
Science) overnight at 4°C, then the epidermis was separated 
from the dermis and placed in TRIreagent (Molecular Research 
Center Inc., Cincinnati, OH).
For the IL-23A and IL-1B real-time (RT)-PCR analysis, addi-
tional 4 control and 4 psoriatic non-involved epidermis samples 
were generated the same way as described above. They were 
also age- and gender-matched to the individuals whose samples 
were used for the original cDnA microarray experiments.
RNA preparation and microarray hybridization
RnA was isolated by using TRIreagent, according to the 
manufacturer’s instructions. The quality of the resulting samp-
les was analysed by using an Agilent Bioanalyzer 2100. Only 
samples containing sufficiently high quality RnA were used 
for further studies.
Labelled cDnA and the subsequent microarray experiments 
were performed by the Microarray Core Facility of the De-
partment of Genetics, Cell- and Immunobiology, Semmelweis 
University, Hungary, using a Whole Human Genom Microarray, 
4x44K (Agilent Technologies).
Data analysis and statistics
Array scanning and feature extraction was performed with 
default scenario by Agilent DnA Microarray Scanner and 
Feature Extraction Software 9.5.3. Total gene signal normali-
sation at the 75th percentile of raw signal values and baseline 
transformation at the median of each array was performed by 
GeneSpringGX software 10.1 (Agilent Technologies Inc.). 
After rejection of outlier features, the expressed genes showing 
a > 2.0-fold differential expression were further analysed by 
statistical t-test using the GeneSpring software 10.1. Genes 
showing a fold change > 2 and p-value < 0.05 were exported 
from GeneSpring.
To analyse the IL-1B and IL-23A gene expression changes 
a non-parametric Wilcoxon test was applied using the SPSS 
software. Statistical significance was determined at p < 0.05.
Literature search
A PubMed search was performed for each identified gene in 
order to identify keratinocyte and/or skin-specific functions, 
and to determine whether they have previously been implicated 
in the pathogenesis of psoriasis. 
Gene ontology analysis
Gene ontology category enrichment analysis was performed, 
using the publicly available software tool DAVID (http://david.
abcc.ncifcrf.gov/, Bethesda, MD) to identify cellular proces-
ses and molecular functions that were overrepresented in our 
dataset. 
Ingenuity pathway analysis
The list of differentially expressed genes was analysed using the 
Ingenuity Pathway Analysis software system (www.ingenuity.
com, Redwood City, CA). Each gene identifier was uploaded 
and mapped to the corresponding gene object in the Ingenuity 
Pathways Knowledge Database. These genes were then used as 
focus points, and possible connections were identified by the 
software. networks of genes were built up algorithmically by 
using the identified connections.
Validation
The microarray results were validated by real-time RT-PCR. 
All the reactions were carried out to quantify the abundance of 
chosen transcripts, using custom primer sets and the Universal 
Probe Library (Roche, Basel, Schweiz) with an iQ Supermix 
(Bio-Rad, Hercules, CA). One microgram of total RnA from 
the organotypic culture samples was reverse transcribed, using 
the iScript TM cDnA Synthesis kit (Bio-Rad, Hercules, CA). 
Relative gene expression data were calculated by normalising 
the expression data for the 18S ribosomal RnA and using the 
Ct method.
RESULTS
Compared to healthy epidermis, non-involved psoriatic 
epidermis exhibits different gene expression changes in 
response to T-cell lymphokine treatment 
We compared the gene expression changes of the pso-
riatic non-involved epidermis with those of the normal 
human epidermis by isolating RnA samples from the 
epidermal compartment of organotypic skin samples 
kept in the presence (referred to below as treated) or ab-
sence (referred to as untreated) of T-cell lymphokines. 
The generated labelled cDnA samples were analysed 
by microarray hybridisation. For all the control and 
psoriatic non-involved samples, we determined gene 
expression changes following T-cell lymphokine treat-
ment by comparing treated samples with autologous 
untreated ones. First, common genes showing at least 
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2-fold up- or downregulation on average were chosen. 
next, we selected all those transcripts that exhibited 
different mean expression changes between the control 
and psoriatic non-involved samples. Sixty-one known 
genes and 11 expressed transcripts met the above cri-
terion (Table SI1).
Twelve differentially regulated genes with known functions 
have already been connected to the pathogenesis of 
psoriasis
PubMed search identified genes that had been already 
implicated in the pathogenesis of psoriasis. Among 
the 61 differentially regulated genes, we identified 12 
that met this criterion (Table I), representing ~20.0% 
of the dataset. 
Some of these genes (e.g. IL-1A, IL-1B, IL-23A and 
TNC) play important roles in the regulation of im-
mune and inflammatory processes, while others (e.g. 
KLK6, PRSS27 and ARG1) do so in the regulation of 
cell growth, proliferation and differentiation. The list 
included known members of the interleukin family (IL-
23A, IL-1A and IL-1B), which serve a central role in 
the pathogenesis of psoriasis (11). MMP9 is an enzyme 
contributing to inflammatory responses and subsequent 
tissue remodeling especially in psoriatic arthritis (12). 
TNC was another gene with differential expression 
changes in response to T-cell lymphokines. This result 
is in agreement with earlier findings showing elevated 
tNC immunostaining in the superficial dermis and at 
the epidermal-dermal junction after scarification and 
induction of the Koebner reaction in non-involved skin 
of psoriatic patients (13). 
Trypsine-like serine proteases (KLK6, PRSS27 and 
TMPRSS11D) have been shown to exhibit a gradually 
increasing expression in normal, non-involved and lesi-
onal psoriatic skin samples (14–16). ARG1, an important 
player in nitric oxide (nO) metabolism has also been 
shown to be elevated in psoriatic tissues, resulting in low 
nO levels that may contribute to the hyperproliferation 
of epidermal keratinocytes in psoriatic patients (17). 
We additionally identified FABP7 and SPRR3, close 
relatives of the well-known psoriatic markers FABP5 
and SPRRs, respectively, involved in atypical cellular 
organisation and differentiation in psoriasis pathogene-
sis (18). We also picked out IFI27 from our experiment, 
a gene that has been reported to display an elevated 
expression in most large-scale genetic investigations 
on psoriasis, independently of donor gender, age and 
ethnicity. It plays an important role in stress response 
and possibly in apoptosis regulation (19). 
Gene ontology analysis
In order to identify biological processes that might be 
differentially regulated in psoriatic non-involved ke-
ratinocytes after lymphokine treatment, we performed 
gene ontology analysis, using the publicly available 
software tool DaVID, with the list of the identified 61 
known genes. Cytokine-mediated signalling proces-
ses and the response to wounding were significantly 
represented by genes in our dataset (p < 0.05), while 
the regulation of apoptosis and apoptotic processes was 
also at the border of significance (table II).
Ingenuity pathway analysis
Ingenuity pathway analysis suggested that many of 
the identified genes fell into two categories: pathways 
involving the regulation of cell morphology, cell de-
velopment and cell death, and pathways involving the 
metabolism of small molecules and lipids. 
In the former pathway, all the genes involved seem to 
be organised around three molecules; INFγ (11), tumour 
necrosis factor α (tNFα) (20) and signal transducer and 
activator of transcription 3 (STAT3) (21). none of them 
are present in our list of differentially expressed genes, 
but all of them are known important regulators of key 
processes in the pathogenesis of psoriasis. 
Similarly, in pathways involving the metabolism of 
small molecules and lipids, the genes are organised 
around IFNγ and β-estradiol. although these genes were 
not present in our list, the encoded proteins are known 
Table I. Twelve of the differentially expressed genes were previously implicated in the pathogenesis of psoriasis
Genebank accession. no. Gene name Function Reference
nM_018399 VNN3 (vanin 3) Inflammation, metabolism Jansen, et al. 2009 (32)
nM_002160 TNC (tenascin C) Immune regulation, inflammation, proliferation Capuano, et al. 1999 (13)
nM_001012964 KLK6 (kallikrein-related 6) Tumour growth, proliferation, differentiation Komatsou, et al. 2007 (15)
nM_031948 PRSS27 (serine protease 27) Proliferation, differentiation Li, et al. 2009 (16)
nM_004262 TMPRSS11D (serine protease) Cell growth, proliferation Iwakiri, et al. 2004 (14)
nM_005416 SPRR3 (small proline-rich protease 3) Differentiation Koizumi, et al. 1996 (33)
nM_000045 ARG1 (arginase 1) Proliferation, differentiation Bruch-Gerharz, et al. 2003 (17)
nM_005532 IFI27 (interferon, alpha-inducible protein 27) Stress response, apoptosis Suomela, et al. 2004 (19)
nM_004994 MMP9 (matrix metallopeptidase 9) Tissue reorganization Cordiali-Fei, et al. 2007 (12)
nM_016584 IL-23A (interleukin-23A) Immune regulation, inflammation Pietrzak, 2008 (11)
nM_000575 IL-1A (interleukin 1A) Immune regulation, inflammation Pietrzak, 2008 (11)
nM_000576 IL-1B (interleukin 1B) Immune regulation, inflammation Pietrzak, 2008 (11)
1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-1708
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to play major roles in the pathogenesis of psoriasis 
(Fig. S11) (5).
Validation of the chip results by real-time-PCR
In order to validate the chip results, real-time RT-PCR 
analysis was performed on selected genes, using the 
original RnA samples that were applied in the cDnA 
microarray experiment. These results indicated a coordi-
nated upregulation of gene expressions for many genes 
(e.g IFI27, VNN3, AGPAT9 and LAMC2) in the healthy 
epidermal samples in response to T-cell lymphokines, 
whereas no such upregulation could be detected in the 
psoriatic non-involved samples in response to the same 
treatment (Fig. S2a1). The lack of upregulation could 
have been due to the fact that expressions of the different 
genes were already higher in the psoriatic non-involved 
untreated epidermis, and thus they were resistant to 
further stimuli (Fig. S2b1). All these results correlated 
well with the cDnA microarray data (data not shown).
Differential regulation of pro-inflammatory cytokine 
genes in healthy and in psoriatic non-involved epidermal 
samples in response to T-cell lymphokines
the gene expression changes of the pro-inflammatory 
cytokines IL-1β and IL-23 in response to lymphokine 
treatment were also analysed by real-time RT-PCR, 
using the original RnA samples together with additional 
4 control and 4 psoriatic uninvolved epidermis samples. 
The mRnA expression of both genes was upregulated 
in response to T-cell lymphokines in the healthy epi-
dermis samples (IL-23A: p = 0.043; IL-1B: p = 0.063), 
but no such changes were observed in the psoriatic non-
involved epidermis compared to the untreated values 
(IL-23A: p = 0.208; IL-1B: p = 0.865; Fig. 1). There was a 
tendency for higher basal expression of both genes  (IL-
23A: 2.2 fold, IL-1B: 2.4 fold) in the untreated psoriatic 
non-involved epidermis samples compared to untreated 
healthy control skin (data not shown).
DISCUSSIOn
The trigger of keratinocyte proliferation during the 
initiation of psoriatic lesions is thought to be the activa-
tion of the cellular immune system, involving T cells, 
dendritic cells and various immune-related cytokines 
and chemokines (2). Psoriatic T cells have traditionally 
been regarded as the central players in the pathogene-
sis of the disease, but they only seem to acquire their 
pathogenic phenotype in a psoriatic environment (3). 
This suggests that dysfunctions of both the skin and the 
immune system are required for the development of the 
disease. Lesional CD4+ T cells produce a mixture of 
lymphokines that are growth stimulatory for psoriatic 
non-involved basal keratinocytes (3). In vitro recom-
binant IFNγ in the presence of gM-CsF and IL-3 can 
mimic this effect (3). 
In order to gain deeper insight into this functional 
difference and the underlying regulatory networks 
that function differentially in healthy and in psoriatic 
non-lesional keratinocytes, we compared gene expres-
sion changes following T-cell lymphokine treatment in 
vitro, and selected all the genes that were differentially 
regulated. Our list of genes only partially overlapped 
with results of previous large- scale gene expression 
studies comparing the transcriptional profile of healthy 
and lesional psoriatic epidermis. The reason for that is 
currently not known. One explanation may be that our 
experimental setup allowed us to determine functional 
differences between the healthy and psoriatic epidermis. 
Alternatively, some differences may be explained by 
different gender, age, skin type, genetic background and 
ethnicity of the donors in the different studies. A large 
proportion of our identified genes were earlier described 
in connection with psoriasis pathomechanism sugges-
Table II. Gene ontology analysis identified biological processes 
that are significantly represented in the dataset
Gene ontology term p-value Genes, n
Cytokine mediated signaling processes 0.0017 4
Response to wounding 0.0087 7
Apoptosis 0.052 6
Regulation of apoptosis 0.053 7
According to the gene ontology analysis, cytokine-mediated signaling 
processes and the response to wounding were significantly represented by 
genes in our dataset (p < 0.05), while the regulation of apoptosis and apoptotic 
processes was at the border of significance.
Fig. 1. RT-PCR experiments show differences in expression of IL-1B and 
IL-23 in healthy and in psoriatic non-involved epidermis samples (pso) 
following T-cell lymphokine treatment in vitro. (A) A trend for elevated IL-1B 
expression levels are detected in the healthy epidermis samples (p = 0.063), 
whereas no such changes are noted in the psoriatic non-involved samples. 
(B) statistically significant IL-23A gene expression changes are detected 
in the control epidermis samples (p = 0.043), whereas no such changes 
are noted in the psoriatic non-involved samples. (Statistical analysis was 
performed using the non-parametric Wilcoxon test), T-cell lymphokine 
treated samples were compared to the untreated ones. Horizontal lines 
represent mean values.
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ting that our experimental design was indeed capable 
to identify pathogenetically important genes (Table I).
next, in silico analysis was used to organise the 
genes into networks using publicly available software 
tools. We found the deregulation of apoptosis and lipid 
metabolism as major factors responsible for the altered 
responsiveness to lymphokine treatment of psoriatic 
non-involved keratinocytes. 
Together with hyperproliferation, decreased apopto-
sis plays an important role in the increased rate of cell 
production in the psoriatic epidermis (22), and this 
gene network was organised around TNFA, IFNG and 
STAT3. another identified pathway was the metabo-
lism of small molecules and lipids. These results are in 
accord with results of previous studies, showing that 
genes important in lipid and fatty acid metabolisms 
are abnormally regulated in the non-involved skin of 
psoriatic patients (5, 6). This network was organised 
around IFNγ and, interestingly, β-estradiol.  although 
IFNγ was not present  in our actual dataset, it is known 
to be a central organiser of various pathogenic processes 
during psoriatic lesion formation. On the other hand, 
β-estradiol, may link these genes by possibly regulating 
them upon treatment.
Many of the identified genes were upregulated upon 
treatment of healthy tissue samples, whereas downre-
gulation, or no changes were detected in the psoriatic 
non-involved samples. It is noteworthy that many genes 
were already upregulated in the untreated non-involved 
psoriatic epidermis samples compared to healthy ones, in-
cluding the pro-inflammatory cytokine genes IL-23a and 
IL-1B, even before obvious inflammatory changes occur. 
Together with the fact that treatment of the patients with 
anti-p40 blocking antibodies targeting both IL-12 and 
IL-23 clearly results in an improvement of the patients’ 
symptoms (24) our results reinforce the importance of the 
IL-23 axis in the pathogenesis of psoriasis. However, the 
development of the pathogenic T-helper 17 (TH17) cells 
relies on the presence of IL-1β. Furthermore, constitutive 
IL-1β activation in mice results in a tH17 cytokine pro-
file, and the appearance of psoriasiform skin lesions, even 
in the absence of T cells (25). All these data, together with 
our results strongly argues that the improper regulation 
of early innate immune events to some unknown stimuli 
is a key factor in the pathogenesis of psoriasis.
In the non-lesional skin of psoriatic patients the 
microscopical structure of the skin seems normal, but 
the keratinocytes exhibit a special “wound” or “stress” 
phenotype, and in this state the major sources of the 
elevated IL-23A mRnA levels probably are the kera-
tinocytes (26). 
Later, in the formation of the lesions and in the stable 
plaque the adaptive immune system gets activated, and 
immune cells infiltrate the epidermis. In stable plaques 
the majority of expressed IL-23 is thought to be coming 
from the tissue resident and/or recruited dendritic cells, 
whereas the contribution of keratinocytes may be limi-
ted (23, 26).
Interestingly, this is true not only in the skin but also 
in the gut. In case of experimental colitis, for example, 
IL-23 may have a similar, dual role at the onset of 
disease and in its chronic phase, respectively (27). A 
link between the molecular pathogenesis of these two 
chronic inflammatory conditions is further strengthened 
by the fact that genetic polymorphisms of the IL-23R 
gene, encoding the receptor for IL-23, seem to play a 
role in the genetic predisposition of both conditions 
(28). Moreover, treatment modalities (e.g. biological 
therapies targeting tNFα and IL-23) are similar for 
psoriasis and inflammatory bowel disease. 
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